All Stories

  1. Efficacy of PEGylated ciliary neurotrophic factor superagonist variant in diet-induced obesity mice
  2. Cisplatin liposome and 6-amino nicotinamide combination to overcome drug resistance in ovarian cancer cells
  3. Transglutaminase and Sialyltransferase Enzymatic Approaches for Polymer Conjugation to Proteins
  4. Covalent immobilisation of transglutaminase: stability and applications in protein PEGylation
  5. Transgultaminase-Mediated Nanoarmoring of Enzymes by PEGylation
  6. Recent Developments in Hyaluronic Acid-Based Nanomedicine
  7. Site-Specific Transglutaminase-Mediated Conjugation of Interferon α-2b at Glutamine or Lysine Residues
  8. Thiol-Activated Anticancer Agents: The State Of The Art
  9. A site-selective hyaluronan-interferonα2a conjugate for the treatment of ovarian cancer
  10. Drug and protein delivery by polymer conjugation
  11. Polyethylene glycols: An effective strategy for limiting liver ischemia reperfusion injury
  12. Polyethylene Glycol Preconditioning: An Effective Strategy to Prevent Liver Ischemia Reperfusion Injury
  13. A novel PEG–haloperidol conjugate with a non-degradable linker shows the feasibility of using polymer–drug conjugates in a non-prodrug fashion
  14. Hyaluronic Acid as a Protein Polymeric Carrier: An Overview and a Report on Human Growth Hormone
  15. Chemical and Enzymatic Site Specific PEGylation of hGH: The Stability and in vivo Activity of PEG-N-Terminal-hGH and PEG-Gln141-hGH Conjugates
  16. Drug conjugation to hyaluronan widens therapeutic indications for ovarian cancer
  17. Polyethylene glycol (PEG)-dendron phospholipids as innovative constructs for the preparation of super stealth liposomes for anticancer therapy
  18. Inulin-d-α-Tocopherol Succinate (INVITE) Nanomicelles as a Platform for Effective Intravenous Administration of Curcumin
  19. Peritoneal Tumor Carcinomatosis: Pharmacological Targeting with Hyaluronan-Based Bioconjugates Overcomes Therapeutic Indications of Current Drugs
  20. A hyaluronic acid–salmon calcitonin conjugate for the local treatment of osteoarthritis: Chondro-protective effect in a rabbit model of early OA
  21. Pegylation of Biological Molecules and Potential Benefits: Pharmacological Properties of Certolizumab Pegol
  22. Development of a new hyaluronic acid-calcitonin conjugate for the local treatment of osteoarthritis
  23. Enzymatic Formation of PEGylated Oligonucleotides
  24. Polymers for Protein Conjugation
  25. Polyethylene glycol rinse solution: An effective way to prevent ischemia-reperfusion injury
  26. Chemical and Enzymatic Site Specific PEGylation of hGH
  27. Conjugation of hyaluronan to proteins
  28. Polysialic acid as a drug carrier: evaluation of a new polysialic acid–epirubicin conjugate and its comparison against established drug carriers
  29. Liver Graft Washout Prevents Against Reperfusion Injury: Protective Effects on Glycocalyx and Cytoskeleton
  30. State of the art in PEGylation: The great versatility achieved after forty years of research
  31. Selective conjugation of poly(2-ethyl 2-oxazoline) to granulocyte colony stimulating factor
  32. Protein PEGylation
  33. Dendritic Poly(ethylene glycol) Bearing Paclitaxel and Alendronate for Targeting Bone Neoplasms
  34. A new method to increase selectivity of transglutaminase mediated PEGylation of salmon calcitonin and human growth hormone
  35. Multivalent and Flexible PEG-Nitrilotriacetic Acid Derivatives for Non-covalent Protein Pegylation
  36. Polyoxazoline: Chemistry, Properties, and Applications in Drug Delivery
  37. Covalent Conjugation of Poly(Ethylene Glycol) to Proteins and Peptides: Strategies and Methods
  38. Relevance of folic acid/polymer ratio in targeted PEG–epirubicin conjugates
  39. PEG conjugates in clinical development or use as anticancer agents: An overview
  40. Polymer−Drug Conjugates for Combination Anticancer Therapy: Investigating the Mechanism of Action
  41. Poly(ethylene glycol)-Protein, Peptide, and Enzyme Conjugates
  42. A Biodegradable Polymeric Carrier Based on PEG for Drug Delivery
  43. PEG: a useful technology in anticancer therapy
  44. Protein PEGylation, basic science and biological applications
  45. PEGylated α interferons: two different strategies to achieve increased efficacy
  46. Pegylation for improving the effectiveness of therapeutic biomolecules
  47. A New PEG−β-Alanine Active Derivative for Releasable Protein Conjugation
  48. PEGylation: Posttranslational bioengineering of protein biotherapeutics
  49. Anti-cancer PEG-enzymes: 30 years old, but still a current approach
  50. Site-Specific Pegylation of G-CSF by Reversible Denaturation
  51. Cardiac safety and antitumoral activity of a new nitric oxide derivative of pegylated epirubicin in mice
  52. Polymer–drug conjugation, recent achievements and general strategies
  53. New active poly(ethylene glycol) derivative for amino coupling
  54. Drug–Polymer Conjugates
  55. Nitric oxide modulates proapoptotic and antiapoptotic properties of chemotherapy agents: the case of NO-pegylated epirubicin
  56. Basic Strategies for PEGylation of Peptide and Protein Drugs
  57. PEGylated Proteins as Cancer Therapeutics
  58. Novel Monodisperse PEG−Dendrons as New Tools for Targeted Drug Delivery:  Synthesis, Characterization and Cellular Uptake
  59. PEGylation of Proteins as Tailored Chemistry for Optimized Bioconjugates
  60. PEGylation, successful approach to drug delivery
  61. PEG-metronidazole conjugates: synthesis, in vitro and in vivo properties
  62. PEG−Doxorubicin Conjugates:  Influence of Polymer Structure on Drug Release, in Vitro Cytotoxicity, Biodistribution, and Antitumor Activity
  63. PEG-epirubicin Conjugates with High Drug Loading
  64. Poly(ethylene glycol)-Poly(ester-carbonate) Block Copolymers Carrying PEG-Peptidyl-Doxorubicin Pendant Side Chains:  Synthesis and Evaluation as Anticancer Conjugates
  65. Highly Efficient Technetium-99m Labeling Procedure Based on the Conjugation ofN-[N-(3-Diphenylphosphinopropionyl)glycyl]cysteine Ligand with Poly(ethylene glycol)
  66. Protein, peptide and non-peptide drug PEGylation for therapeutic application
  67. PEG–Ara-C conjugates for controlled release
  68. Synthesis, characterization and preliminary cytotoxicity assays of poly(ethylene glycol)–malonato–Pt–DACH conjugates